GE Healthcare and Dharmacon, Benitec, NCI and NIH, and New York Academy of Sciences | GenomeWeb

GE Healthcare to Market Dharmacon RNAi Products in Japan

Dharmacon said this week that it has signed a deal making GE Healthcare the exclusive distribution agent for its RNAi research products in Japan.

Specific terms of the arrangement were not disclosed.


Benitec Names Cancer as Third Disease Area

Benitec reported in its annual general meeting presentation last week that cancer is the third disease area on which the company will focus its drug-development efforts.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.